nafamostat has been researched along with Syndrome in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Syndrome: A characteristic symptom complex.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ryu, HG | 1 |
| Jung, CW | 1 |
| Lee, CS | 1 |
| Lee, J | 1 |
1 trial available for nafamostat and Syndrome
| Article | Year |
|---|---|
Nafamostat mesilate attenuates Postreperfusion Syndrome during liver transplantation.
Topics: Adult; Benzamidines; Double-Blind Method; Female; Guanidines; Humans; Infusions, Intravenous; Kallik | 2011 |